Vanda settles its squabble with Novartis and pockets $25M for its trouble

Vanda Pharmaceuticals ($VNDA) has come out at the other end of its dispute with former partner Novartis ($NVS), getting back the rights to its schizophrenia drug and banking an equity investment from the Swiss drugmaker.

In 2009, Novartis bought the U.S. and Canadian rights to Vanda's Fanapt in a deal worth up to $465 million, working to crack the market with what many perceived as a me-too drug. Fanapt never lived up to the partners' hopes, however, and the deal bubbled over into a dispute this May, with Vanda demanding $539 million and Novartis responding with a counter claim.

Now, under the pair's final agreement, Vanda regains the full rights to Fanapt, and Novartis has agreed to make a $25 million investment in the company. Vanda also gets a worldwide exclusive license to Novartis' AQW051, a Phase II treatment for schizophrenia.

The deal "has the potential to be transformational for our company," CEO Mihael Polymeropoulos said in a statement, and the news sent Vanda's shares soaring more than 20% on Tuesday morning.

Beyond Fanapt, Vanda's portfolio includes Hetlioz, approved early this year to treat a sleep disorder called non-24, and VLY-686, an anti-itching drug.

- read the statement

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.